Under the assumption that even if LDL-cholesterol may not be the relevant causal risk factor, it is a relevant prognostic factor for assessing the degree of HMGCR inhibition, this suggests that any reduction in cancer risk from statins in practice is likely to be modest. The gene discussed is HMGCR; the disease is cancer.